Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
argenx is seeking a seasoned Commercial Asset Lead for FB102, a first-in-class anti-CD122 antibody. You will drive market access, product strategy, and lifecycle activities while coordinating with regional teams to maximize asset value across indications.
The role requires 15+ years in biopharma marketing/commercial roles, strong cross-functional leadership, and US and global launch experience. Travel ~30% and a high-performance, data-driven culture are expected.
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.
We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients.
argenx is a global immunology company developing innovative potential therapies to help improve the lives of people suffering from severe autoimmune diseases. Our global team across Boston, Ghent, Japan, Canada, broader Europe and Emerging markets are committed to living by our values of co-creation, empowerment, humility, innovation and excellence. As we continue to expand our therapeutic franchises (ie neuromuscular, rheumatology, dermatology and nephrology) we remain science-based, data-driven and patient-focused. We listen to those we aim to serve, so we can best integrate their goals and aspirations into our work on their behalf. It is an exciting time to join this growth company.
The FB102 Lead is accountable for the commercial development and launch preparations for FB102, a first-in-class anti-CD122 (IL-2Rβ) monoclonal antibody originally developed by Forte Biosciences and acquired by argenx in 2026. It is aimed to be a portfolio in a product with potential in multiple indications such as vitiligo, celiac disease, and alopecia. In this senior leadership role, you will be a key member on the Global FB102 Asset team. You will collaborate across all domains of expertise, geographies and business units to create and deliver integrated strategic plans to optimize the value of our FB102 asset. You will serve as the commercial voice on the asset team and set commercial strategy for the asset.
For applicants in the United States: The annual base salary hiring range for this position is $236,000.00 - $324,500.00 USD. This range reflects our good faith estimate at the time of posting. Individual compensation is determined using objective, inclusive, and job-related criteria such as relevant experience, skills, demonstrated competencies and internal equity. This means actual pay may differ from the posted range when justified by these factors. Because market conditions evolve, pay ranges are reviewed regularly and may be adjusted to remain aligned with external benchmarks.
This job is eligible to participate in our short-term and long-term incentive programs, subject to the terms and conditions of those plans and applicable policies. It also includes a comprehensive benefits package, including but not limited to retirement savings plans, health benefits and other benefits subject to the terms of the applicable plans and program guidelines.
At argenx, all applicants are welcomed in an inclusive environment. They will receive equal consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other applicable legally protected characteristics. argenx is proud to be an equal opportunity employer.